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ABSTRACT 
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer of adalimumab (AbbVie) to submit evidence on the clinical 
effectiveness and cost-effectiveness of adalimumab for the treatment of moderate-to-severe hidradenitis 
suppurativa (HS). The appraisal assessed adalimumab as monotherapy in adult patients with an 
inadequate response to conventional systemic HS therapy. The School of Health and Related Research 
Technology Appraisal Group was commissioned to act as the independent Evidence Review Group 
(ERG). The ERG produced a critical review of the evidence for the clinical effectiveness and cost-
effectiveness of the technology, based on the company’s submission to NICE. The evidence was mainly 
derived from three randomised controlled trials comparing adalimumab with placebo in adults with 
moderate-to-severe HS. The clinical effectiveness review found that significantly more patients 
achieved a clinical response in the adalimumab groups than the control groups, but that the treatment 
effect varied between trials and there was uncertainty regarding its impact on a range of other relevant 
outcomes, as well as long-term efficacy. The company’s submitted state transition model assessed the 
incremental cost-effectiveness of adalimumab versus standard care for the treatment of HS from the 
perspective of the National Health Service (NHS) and Personal Social Services (PSS) over a lifetime 
horizon. The original submitted model, which included a Patient Access Scheme (PAS), suggested that 
the incremental cost-effectiveness ratio (ICER) for adalimumab versus standard care is expected to be 
£16,443 per QALY gained. Following a critique of the model, the ERG’s preferred base case, which 
corrected programming errors and structural problems surrounding discontinuation rules, and 
incorporated a lower unit cost for HS surgery, resulted in a probabilistic ICER of £29,725 per QALY 
gained. Based on additional analyses undertaken by the company and the ERG following the publication 
of the Appraisal Consultation Document (ACD), the appraisal committee concluded that the maximum 
possible ICER for adalimumab compared with supportive care was between £28,500 and £33,200 per 
QALY gained, but was likely to be lower. The appraisal committee recommended adalimumab (with 
the PAS) for the treatment of active moderate-to-severe HS in adults whose disease has not responded 
to conventional systemic therapy. 
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KEY POINTS FOR DECISION-MAKERS  Based on evidence provided from 3 RCTs and one OLE study, the Appraisal Committee agreed 
that adalimumab is efficacious and safe in producing a clinical response in adults with 
moderate-to-severe hidradenitis suppurativa (HS) with an inadequate response to conventional 
systemic therapy.  There was uncertainty regarding the long-term effectiveness and safety of adalimumab, the cost 
of the surgical comparator and the definitions of “partial response” and “no response” based on 
the HiSCR measure.  Based on the ERG’s exploratory analyses, the committee concluded that the maximum possible 
ICER for adalimumab, compared with supportive care, was between £28,500 and £33,200 per 
QALY gained, but was likely to be lower. 
 
  
4 
 
1. INTRODUCTION 
Health technologies must be shown to represent a clinically effective and cost-effective use of resources 
in order to be recommended for use within the NHS in England. The National Institute for Health and 
Care Excellence (NICE) is an independent organisation responsible for providing national guidance on 
promoting good health and preventing and treating ill health in priority areas with a significant impact. 
The NICE Single Technology Appraisal (STA) process usually covers new technologies within a single 
indication, shortly after they have received UK marketing authorisation [1]. Within this process, the 
company provides NICE with a written submission that summarises the company’s estimates of the 
clinical effectiveness and cost-effectiveness of the technology, together with an executable health 
economic model. The company’s submission (CS) is reviewed by an external organisation independent 
of NICE, the Evidence Review Group (ERG), which consults with clinical specialists and produces an 
ERG report. After consideration of the CS, the ERG report and testimony from experts and other 
stakeholders, the NICE Appraisal Committee formulates preliminary guidance in the form of an 
Appraisal Consultation Document (ACD) which indicates the Committee’s initial recommendations on 
the use of the technology. Stakeholders are subsequently invited to comment on the submitted evidence 
and the ACD, after which a subsequent ACD may be produced or a Final Appraisal Determination 
(FAD) is issued, which is open to appeal. An ACD is not produced when the technology is 
recommended without restriction; in such instances, the FAD is produced directly. This paper presents 
a summary of the ERG report [2] and subsequent analyses [3, 4] for the STA of adalimumab for the 
treatment of active moderate-to-severe hidradenitis suppurativa (HS), and the subsequent development 
of the NICE guidance for the use of this drug in England [5]. Full details of all relevant appraisal 
documents can be found on the NICE website (https://www.nice.org.uk/guidance/ta392).  
 
2. THE DECISION PROBLEM 
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, inflammatory, recurrent, 
debilitating, skin follicular disease that usually presents after puberty with painful deep-seated, inflamed 
lesions. In patients with HS, hair follicles in the apocrine gland-bearing regions (axilla, genital area, 
groin, infra-mammary region, peri-anal region and buttocks) become blocked and inflamed, resulting 
in painful recurrent deep-seated boils and nodules. Boils and nodules may progress to abscesses, sinus 
tracts and scarring. In most patients, disease flares occur at varying intervals, often pre-menstrually in 
women. Disease flares are characterised by increased pain and suppuration with a foul smelling 
discharge which stains clothing. HS affects young adults, with disease onset typically between the 
second and fourth decades of life [6, 7]. Within the adult European population, a prevalence of 1% has 
been reported [8], although true prevalence is likely to be higher due to problems of under-recognition 
[9, 10]. Whilst there are no published data on HS prevalence in the UK, it has been suggested that this 
might be in the region of 1 in 600 [6]. HS has a higher prevalence in women than men and around one-
third of patients have a disease in first-degree relatives. The other important known risk factors for HS 
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are obesity and cigarette smoking [8-10]. Studies have suggested that active disease can substantially 
impair patients’ health-related quality of life (HRQoL), with an impact which exceeds that of other skin 
diseases such as alopecia, acne, mild to moderate psoriasis, vascular anomalies of the face and atopic 
dermatitis. Given the debilitating impact of HS, measures of pain and HRQoL, especially the 
Dermatology Quality of Life Index (DLQI), are recognised as being useful for clinical management of 
the disease [8, 10]. 
 
2.1 Current treatment 
There is no current standard of care for HS in England. Treatment is usually determined by the specifics 
of the disease in the individual patient, together with clinical and patient experience. Treatment usually 
aims to control the disease and to reduce the number of outbreaks; total cure is generally not expected. 
Alongside lifestyle changes (smoking cessation and weight loss), therapeutic options include topical 
antiseptics and antibiotics, systemic antibiotics (e.g. oral tetracyclines, clindamycin and rifampicin), 
anti-androgens, systemic retinoids, immunomodulatory agents, laser treatment, surgery and tumour 
necrosis factor-alpha (TNF-α) inhibitors [11-13]. Treatment choices typically depend on the frequency, 
severity and spread of lesions and also gender in the case of the retinoid acitretin. A survey of current 
practice among UK dermatologists confirmed that, after topical treatments, oral antibiotics, such as 
lymecycline or doxycycline, represent the first-line medical treatment of choice, followed by 
clindamycin and rifampicin, dapsone, acitretin, ciclosporin, depending on response and gender [13]. In 
addition, TNF-α inhibitors, such as etanercept, infliximab and adalimumab are already being used for 
the treatment of moderate-to-severe HS in England. Surgery is usually an option after medical 
treatments have failed and might involve simple local incision and drainage (usually as a response to 
acute flares, rather than to control the disease or reduce recurrence); narrow margin excision (which 
might see recurrence at the edge of the excised area), and; wide margin excision for patients with 
advanced disease.  
 
In October 2015, NICE issued a final scope to appraise the clinical effectiveness and cost-effectiveness 
of adalimumab for active moderate-to-severe HS in adult patients with an inadequate response to 
conventional systemic HS therapy [14]. 
 
3. INDEPENDENT ERG REVIEW 
The company (AbbVie) provided a submission to NICE on the clinical effectiveness and cost-
effectiveness of adalimumab for the treatment of moderate-to-severe HS [15]. This submission was 
critically appraised by the ERG. In addition, the ERG identified areas requiring clarification, for which 
the company provided additional evidence prior to completion of the ERG report [16].  
 
3.1.1 Clinical evidence submitted by the company 
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The clinical evidence consisted of three separate reviews: (1) a review of clinical efficacy evidence 
from RCTs of treatments for HS, specifically trials comparing adalimumab with placebo in adults with 
moderate-to-severe HS: a Phase II “dosing” trial, M10-467 [17], and two Phase III trials, PIONEER I 
and II [18, 19]; (2) a review of evidence from a non-controlled open-label extension (OLE) study (M12-
555) [20], and; (3) a review of safety evidence from the RCTs and the OLE study. The relevant efficacy 
data were derived from Period 1 of the M10-467 trial (up to week 16) and Periods A and B in the 
PIONEER trials, i.e. weeks 0-12 and weeks 12-36, respectively. The initial periods in all trials compared 
adalimumab 40mg every week (EW) with placebo. The second period in the PIONEER trials was 
initiated by re-randomisation of patients at week 12 to adalimumab 40mg EW, placebo or adalimumab 
40mg every other week (EOW). The three RCTs and the OLE study were all reported by the company 
to be at low risk of bias following quality assessment using a range of critical appraisal tools [15].  
 
In M10-467, significantly more patients in the adalimumab 40mg EW group achieved a clinical 
response (defined as achieving a Hidradenitis Suppurativa Physician’s Global Assessment [HS-PGA] 
score of clear, minimal or mild with at least a 2 grade improvement relative to baseline at week 16) than 
patients receiving placebo: 17.6% versus 3.9% (p<0.025). Significant improvements were also observed 
at week 16 in individual symptoms, overall disease severity and pain scores for adalimumab 40mg EW 
compared with placebo. In the PIONEER trials, clinical response was evaluated by Hidradenitis 
Suppurativa Clinical Response (HiSCR), defined as ≥50% reduction in the total abscess and 
inflammatory nodule [AN] count with no increase in abscess count or draining fistula count [17]. In 
Period A of PIONEER I and II (at week 12), significantly more patients in the adalimumab 40mg EW 
group achieved clinical response relative to baseline compared with patients receiving placebo 
(PIONEER I – adalimumab 41.8%, placebo 26.0%, p=0.003; PIONEER II – adalimumab 58.9%, 
placebo 27.6%, p<0.001). Significant improvements were observed in symptoms, disease severity 
(according to the Modified Sartorius Severity [MSS] score) and pain in PIONEER II. However, in 
PIONEER I, some of the improvements with adalimumab 40mg EW were numerically but not 
significantly better than placebo. Subgroup analyses indicated that patients achieved benefit with 
adalimumab 40mg EW regardless of their baseline characteristics, although analyses were subject to 
small patient numbers. In PIONEER I and II, adalimumab 40mg EW significantly improved HRQoL 
as measured by the EQ-5D, the DLQI, and the physical components of the Short-Form 36 (SF-36) 
compared with placebo; improvements were not significant across all components of SF-36. The 
treatment effect therefore varied between the trials. The CS did not include a pairwise meta-analysis of 
the PIONEER trials and a network meta-analysis (NMA) was not considered feasible. 
 
Some improvements were maintained into the second period of the PIONEER trials up to 36 weeks 
(Period B). During Period B, there was also a loss of effect for patients re-randomised to placebo or 
adalimumab 40mg EOW. The company stated that re-randomisation at week 12 and protocol-driven 
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discontinuation during Period B for patients with Loss of Response (LOR) or Worsening or Absence 
of Improvement (WOAI), led to low patient numbers in the group receiving adalimumab 40mg EW for 
the total study duration, meaning the analyses were underpowered.  
 
These trials were supplemented by one unpublished, non-randomised, non-controlled, unblinded OLE 
study of the PIONEER trials (M12-555 OLE). The CS included an interim analysis of efficacy from 
this study, however patient numbers were small. Results for secondary efficacy outcomes were not 
reported. 
 
The review of safety evidence included the three RCTs and the OLE study. Adalimumab 40mg EW 
was well-tolerated in all three RCTs. The proportion of patients experiencing serious adverse events 
(SAEs) or discontinuing treatment due to AEs was low and was similar in both the adalimumab and 
placebo arms. In an integrated summary of PIONEER I and II (n=633), six patients receiving placebo 
(1.9%) and three receiving adalimumab 40mg EW (0.9%) gave AEs as their primary reason for 
discontinuation during Period A. The most common AEs were exacerbation of HS, nasopharyngitis and 
headache. Rates of infectious AEs were similar for patients receiving adalimumab and for those 
receiving placebo. M12-555 is the only ongoing study of adalimumab for HS; final data were not 
available at the time of the appraisal. 
 
3.1.2 Critique of clinical effectiveness evidence and interpretation 
The principal efficacy review was a poorly-reported systematic review of 3 relevant RCTs. The 
PIONEER trials were published only as abstracts, so clinical study reports (CSRs) provided by the 
company were the principal source of data and were used for quality assessment purposes. The primary 
outcome was clinical response, measured in the PIONEER trials using the HiSCR measure developed 
by the company. Clinical advice received by the ERG confirmed that HiSCR had been validated but, in 
terms of clinical decision-making, its findings should be viewed alongside patient-reported outcome 
measures (PROMs), in particular the DLQI and a pain measure [17, 21]. The ERG agreed with the 
company that the M10-467 trial was at low risk of bias for the relevant Period 1 (up to week 16). The 
ERG also conducted a critical appraisal of the RCTs using the Cochrane Risk of Bias tool [22] and the 
OLE study using the Critical Appraisal Skills Programme (CASP) cohort study tool [23]. The ERG 
considered the results from Period A (up to week 12) in PIONEER I and II to be generally at low risk 
of bias. However, the ERG considered there to be a moderate or unclear risk of selection, attrition and 
reporting bias affecting the results of Period B in the PIONEER trials, given the absence of any 
evaluation of blinding, the high levels of attrition, the imputation methods used to manage some of the 
missing data, and some differences between the outcomes reported in the protocol and those reported 
in the publications and study reports. 
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The ERG accepted that the percentage of patients achieving clinical response according to the HiSCR 
measure on adalimumab 40mg EW at week 12 or week 16 was significantly higher than in the placebo 
groups (p<0.01), but that the treatment effect varied between the trials. Significant or clinically relevant 
differences in favour of adalimumab 40mg EW that were reported for secondary outcomes in PIONEER 
II were not always found for those outcomes in PIONEER I, especially for AN count, MSS score, pain 
and some components of the SF-36. The reasons for these between-trial differences were unclear.  
 
The company conducted an arm-based integrated summary, which breaks randomisation, for the 
PIONEER trials to tabulate Period B response (for all patients and for a group of HiSCR “responders” 
and “partial responders”). This “partial responder” group (defined as HiSCR responders with ≥25% AN 
reduction rather than ≥50% reduction) was not a pre-specified response category in the PIONEER trials, 
nor was it explained or justified in the CS, and its clinical validity had not been demonstrated. The ERG 
considered that findings based on this post hoc “partial responder” group were therefore subject to 
uncertainty. A small number of secondary outcomes were reported for Period B in PIONEER I and II, 
but only for patients who had had a clinical response at week 12, and the sample sizes in this later period 
were small. 
 
The ERG considered the efficacy results from the OLE study to be uncertain because they were drawn 
from interim analyses of unpublished study data. This study also only offered efficacy data for up to 72 
weeks for a drug that might be taken for many years by patients with moderate-to-severe HS. There 
were no obvious safety concerns, with most AEs being balanced between groups, and small numbers 
of SAEs were reported. The ERG considered that longer-term data were required to determine whether 
reported AE rates could be maintained for patients on long-term adalimumab maintenance treatment; 
whether certain subgroups of patients were at a higher risk of certain events, and; to confirm whether 
there were any differences between interrupted and uninterrupted regimens. 
 
3.2 Cost-effectiveness evidence submitted by the company 
The company submitted a de novo Markov model to assess the cost-effectiveness of adalimumab versus 
standard care for moderate-to-severe HS. The company’s model estimates costs and health outcomes 
from the perspective of the National Health Service (NHS) and Personal Social Services (PSS) over a 
lifetime horizon (66 years). Health outcomes and costs were discounted at a rate of 3.5% per annum. 
Costs were valued at 2013/14 prices. All analyses relate to the full licensed population for adalimumab; 
no subgroup analyses were presented. Following the submission of the original ERG report, a Patient 
Access Scheme (PAS) in the form of a confidential price discount was agreed for adalimumab 
specifically in the HS indication. 
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The company’s model includes five mutually exclusive health states, based on depth of HiSCR 
response: (i) high response; (ii) response; (iii) partial response; (iv) no response, and; (v) dead (see 
Table 1). Patients are allowed to transit between any of the living health states during each cycle. The 
model uses a 2-week cycle length for the first 2 cycles, and a 4-week cycle length thereafter. Health 
state transitions were modelled up to week 36 using pooled data from the PIONEER I/II trials, including 
a discontinuation rule for patients receiving adalimumab who do not achieve at least a partial response 
by week 12 (see Table 2). The long-term HiSCR trajectory of adalimumab responders (including partial 
responders) beyond 36 weeks was subsequently modelled using a time-invariant generalised logit model 
(GLM) fitted to last observation carried forward (LOCF)-imputed data from the OLE study. The long-
term HiSCR trajectories for patients receiving standard care and for those who have previously 
discontinued adalimumab beyond 36 weeks were modelled using separate time-invariant GLMs fitted 
to data from weeks 12-36 from the PIONEER I/II trials. The CS stated that the model assumes that 
patients who lose response after week 36 will continue to receive adalimumab for a further 12 weeks, 
although this did not accurately reflect the model’s implementation. Health utilities were based on depth 
of HiSCR response using a post hoc analysis of EQ-5D data collected within PIONEER II. Resource 
use was differentiated by depth of HiSCR response based on a survey of UK physicians undertaken by 
the company and included: inpatient visits due to HS surgery; outpatient visits due to HS surgery; visits 
to wound care due to HS surgery; non-surgical inpatient visits; non-surgical outpatient visits; visits to 
wound care not due to HS surgery; Accident and Emergency (A&E) visits, and; costs associated with 
AEs. Unit costs were taken from the British National Formulary [24], the Personal Social Services 
Research Unit (PSSRU) [25] and NHS Reference Costs [26]. AEs were assumed to impact only on 
costs. 
 
The probabilistic version of the company’s model (including the PAS) suggests that adalimumab is 
expected to produce an additional 1.01 QALYs at an additional cost of £16,640 compared with standard 
care; the incremental cost-effectiveness ratio (ICER) for adalimumab versus standard care is expected 
to be £16,443 per QALY gained. The deterministic results were similar (ICER=£14,952 per QALY 
gained). Assuming willingness-to-pay thresholds of £20,000 and £30,000 per QALY gained, the 
company’s model suggests that the probability that adalimumab produces more net benefit than 
standard care is approximately 0.58 and 0.80, respectively. The ICER for adalimumab was greater than 
£30,000 per QALY gained in four scenario analyses: (i) time horizon=20 years; (ii) use of PIONEER 
II data only; (iii) use of last state carried forward imputation, and; (iv) discontinuation rate for 
adalimumab non-responders after week 36 based on the OLE study.  
 
3.2.1 Critique of cost-effectiveness evidence and interpretation 
10 
 
The ERG critically appraised the company’s economic analysis and double-programmed the company’s 
model. The main issues identified by the ERG are discussed below; the full critique can be found in the 
ERG report and subsequent addenda [2-4]. 
 
3.2.1.1 Appropriateness of modelling according to depth of HiSCR response 
The company’s model structure divides the HiSCR measure into four response categories. The CS 
justified this disaggregation based on a post hoc analysis which suggested statistically significant 
differences in EQ-5D between the high response and response states, and between the partial response 
and non-response states in PIONEER II. The ERG noted the following concerns: 
(i) Disaggregating the full HiSCR measure according to depth of response represents a post hoc 
analysis of a pre-planned endpoint. 
(ii) The HiSCR validation study reported by Kimball et al relates specifically to the full HiSCR 
threshold (≥50% reduction in ANs, with no increase in abscesses or draining fistulas from 
baseline) [17]. Kimball et al reported that patients with worsening disease or minimal 
improvement in ANs (<30% reduction) did not have a meaningful improvement on the DLQI 
and reported some worsening in pain despite improvements in total work impairment and total 
activity impairment. Kimball also reported no substantial incremental benefits on patient 
reported outcomes beyond the ≥50% AN reduction threshold. 
(iii) Efficacy data from the PIONEER I/II trials are “stretched” across four rather than two states, 
hence, several cells in the transition matrices are populated with small patient numbers.  
 
Based on the health state definitions and treatment continuation rules, the company’s model implicitly 
suggests that the 50% AN reduction threshold determined in the Kimball validation study, and later pre-
specified as the primary endpoint in the PIONEER trials, has been set at the wrong level for clinical 
practice. 
 
3.2.1.2 Disconnect between evidence used to inform efficacy and costs 
The company’s modelled health gains and the resources required to generate those health gains were 
derived from different sources: health outcomes were modelled using observed trial data or GLMs fitted 
to HiSCR outcomes from the PIONEER trials, whilst resource use was based on surgery-related and 
non-surgery-related secondary care resource estimates from a survey of UK physicians [15]. Higher 
resource use was assumed for patients achieving a weaker response or no response, hence improvements 
in modelled HiSCR state are assumed to lead to reductions in costs. The ERG had concerns regarding 
whether the company’s modelled predictions of overall resource use reflect the experience of patients 
enrolled into the PIONEER I/II trials. Whilst the CS asserted that adalimumab may delay or reduce the 
need for surgery, and this was reflected in the model, this potential treatment benefit had not been 
substantiated by evidence. As part of the clarification process, the company presented a post hoc 
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analysis of the PIONEER I/II studies which showed that that at week 12, more patients who received 
adalimumab, compared with placebo, experienced elimination of both draining fistulas (33% vs 19%; 
p<0.001) and non-draining fistulas (15% vs 9%; p=0.017). These data do not however directly reflect 
overall reductions in surgery, particularly inpatient surgical admissions, which are a key cost driver in 
the model. Further, the ERG’s advisors noted that whilst the adalimumab could reduce the extent to 
which limited surgical procedures are required for patients with previously uncontrolled disease, it may 
in some instances be used as a preadjuvant “bridge” to more definitive surgery, thereby increasing 
surgery use.  
 
In addition, the costs of pharmacological therapies were not included in the model. Clinical advisors to 
the ERG were satisfied that the types of resource use included were generally relevant, but noted that 
some treatments (e.g. wound dressings, where needed) may be given in a primary care setting and that 
some patients will be prescribed antibiotics by their GPs for several years, yet these costs were not 
considered. Following clarification, the company provided estimates of concomitant medications used 
in >5% patients in Period A of the PIONEER I/II trials. These data suggested that concomitant 
pharmacological therapy use was broadly similar between the adalimumab and placebo groups, 
however this information relates only to the first 12 weeks of treatment within the RCTs and it remains 
unclear whether the inclusion of concomitant medication costs would substantially impact upon the 
cost-effectiveness of adalimumab over a lifetime horizon.  
 
3.2.1.3 Treatment continuation rules 
The model assumes that patients require only a partial HiSCR response in order to continue treatment. 
The ERG’s advisors were unclear whether patients achieving a partial HiSCR response (which could 
include increases in abscesses and/or draining fistulae) would obtain a clinically meaningful benefit 
sufficient to warrant continuing adalimumab treatment. Commentators on the validity of the HiSCR 
measure have highlighted the need to capture other aspects of treatment benefit such as pain and 
improvements on the DLQI [21].  
 
In addition, the company’s model includes an assumption whereby patients receiving adalimumab who 
continue to achieve no response from treatment receive an additional 12 weeks of adalimumab before 
discontinuing. This was applied in the model by raising the probability of remaining in the adalimumab 
no response state for one cycle (from the OLE GLM) to the power of 3 and adjusting all other transitions 
in the row accordingly. This matrix is applied from week 48 onwards. This assumption led to patients 
discontinuing adalimumab more quickly, thereby substantially reducing the total adalimumab treatment 
costs. The ERG noted that this approach is mathematically incorrect as the cubed probability reflects 
the 12-week probability of remaining in the no response state for three 4-week cycles. The proposed 
discontinuation rule should have been implemented using tunnel states. 
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3.2.1.4 Potential overestimation of costs of surgery 
The ERG considered that the company’s model overestimated the lifetime cost of surgery in both 
groups, and that cost savings associated with adalimumab due to surgical procedures avoided, may not 
be realistic. Annual surgical inpatient admission rates according to HiSCR response state were based 
on the company’s physician survey, whilst the unit cost was derived from NHS Reference Costs 
2013/14 (major skin procedures, elective inpatient code JC41Z, length of stay [LOS] = 5.1 days) [26]. 
The company’s model predicted that the average patient receiving standard care will require 33.87 
inpatient surgical admissions over their remaining lifetime, whilst patients receiving adalimumab would 
require 29.78 admissions. The ERG noted that the tariff cost of £5,488.32 and its associated LOS was 
likely to broadly reflect a wide excision procedure. Clinical advisors to the ERG suggested that 
excluding the management of surgical complications, the maximum number of sites which may require 
wide excision for a patient with very extensive disease would be 6-10 (including breasts, groin, the 
perineum, armpits and buttocks). Patients with less extensive disease would require fewer wide 
excisions than this maximum number and in some cases more than one region can be treated in the same 
surgical episode. The ERG’s clinical advisors also suggested that patients may undergo a comparatively 
higher number of smaller less costly procedures such as incision and drainage and narrow margin 
excision.  
 
3.2.1.1 Other issues identified by the ERG 
Several further issues were identified by the ERG, although these had a less significant impact upon the 
ICER for adalimumab. These included: (i) the use of pooled arm-based summaries of trial data rather 
than a formal NMA; (ii) minor programming errors; (iii) inconsistent handling of time-dependence in 
transition probabilities for different time periods, and; (iv) potential bias associated with using the OLE 
data for adalimumab responders. 
 
3.3 Additional work undertaken by the ERG 
The ERG undertook exploratory analyses to resolve the programming errors identified and to explore 
alternative assumptions within the company’s model. The ERG’s preferred base case involved: (a) the 
correction of minor technical programming errors; (b) applying structural amendments to correctly 
reflect the company’s intended adalimumab non-responder continuation rule during the maintenance 
phase, and; (c) re-estimation of surgery costs. The ERG’s surgery cost estimates assumed that patients 
on average undergo 2 wide excisions over their lifetime, with the remaining procedures being 
intermediate day case procedures without admission or elective/non-elective intermediate skin 
procedures with an LOS of 2 days; this resulted in an estimated cost per procedure of £1,525.74. Further 
analyses were undertaken to explore uncertainty surrounding transition probabilities, the likely impact 
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of altering induction phase discontinuation rules and some exploration of uncertainty around the model 
structure.  
 
The ERG’s exploratory analyses indicated that the programming errors did not materially alter the ICER 
for adalimumab. The incorporation of tunnel states for adalimumab non-responders within the 
maintenance phase of the corrected model increased the ICER for adalimumab versus standard care 
(ICER=£19,551 per QALY gained). The ERG’s preferred base case, which comprises a scenario 
whereby these two sets of corrections are combined with the lower surgery cost, resulted in a 
probabilistic ICER of £29,725 per QALY gained.  
 
3.4 Conclusion of the ERG report 
The ERG considered the RCT evidence to be robust for the initial trial periods up to 12 or 16 weeks. 
However, the treatment effect varied between studies; the reasons for this were unclear. Efficacy results 
from Period B of the PIONEER trials were at a higher risk of bias across some domains, and were 
affected by the merging of “responders” with “partial responders.” The safety evidence was generally 
at low risk of bias but was limited, and several questions remain around AE rates for patients on 
“continuous” or long-term adalimumab 40mg EW. The ERG’s exploratory analyses suggested that the 
probabilistic ICER for adalimumab versus standard care is £29,725 per QALY gained. 
 
4. METHODOLOGICAL ISSUES 
The principal areas of uncertainty in the clinical evidence relate to potential treatment effect modifiers 
and short study follow-up. These uncertainties exist due to observed differences in certain outcomes or 
levels of outcome between trials, differences in disease severity and other baseline characteristics 
between trials, and the amount of missing data and imputed results beyond 12 weeks in the PIONEER 
trials and the OLE study. The ERG also noted issues with respect to whether the achievement of a 
“partial response” according to the HiSCR measure represents a clinically meaningful treatment benefit 
sufficient to warrant continuing adalimumab.  
 
The company’s model was subject to several methodological issues. In particular, the ERG had 
concerns that the use of a 5-state model which included three responder categories may have “stretched” 
the available data too far and that a 3-state model (including response, no response and dead) may have 
represented a better use of the available evidence. The ERG also noted a selection bias in that patients 
who discontinued adalimumab after losing a prior response to therapy were assumed to have a different 
trajectory through the model (indefinitely) compared with patients receiving standard therapy alone. 
The joint impact of these issues on the ICER for adalimumab was unclear. 
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5. NICE GUIDANCE 
The appraisal committee reviewed the data available on the clinical effectiveness and cost-effectiveness 
of adalimumab, having considered evidence on the nature of HS and the value placed on the benefits of 
adalimumab by people with the condition, those who represent them, and clinical experts. It also took 
into account the effective use of NHS resources.  
 
The ACD (published February 2016) states that the committee was minded not to recommend 
adalimumab for the treatment of active moderate-to-severe HS. The ACD requested additional analyses 
including: a formal meta-analysis of the PIONEER I/II trials; the committee’s preferred assumption 
about treatment discontinuation for non-responders at 36 weeks or later, a re-analysis of the PIONEER 
I/II data used in the model in which partial response is defined as a 25% to 50% reduction in AN count 
and no increase in abscesses and draining fistulas, and an analysis in which extrapolation of outcomes 
for adalimumab responders was based on the PIONEER I/II trials rather than the OLE study. The ACD 
also requested additional information from the company relating to resource use estimates derived from 
the physician survey, utility values within PIONEER II, methods for deriving transition matrices from 
the OLE study and clarity regarding the company’s attempts to validate model predictions against the 
observed PIONEER I/II data. 
 
Subsequently, the company submitted the requested analyses and additional information. The 
company’s ACD response also included a revised model which incorporated the results of NMAs, the 
correction of programming errors, the committee’s preferred assumption regarding treatment 
discontinuation in non-responders beyond 36 weeks and some structural changes. The revised model 
retained the original surgery cost of £5,488.32 per episode.  
 
The ERG was broadly satisfied that the NMA had been undertaken appropriately. However, within the 
revised model, the NMA-derived transition matrices had been erroneously inverted (transitions to states 
1, 2, 3, and 4 were inputted as transitions to states 4, 3, 2, and 1). In addition, the ERG identified a 
further error whereby the incorrect discontinuation rate was applied during weeks 12-36. Rectifying 
these errors reduced the ICER to £10,077 per QALY gained. The ERG raised concerns regarding an 
unwritten assumption whereby different transition matrices were applied to adalimumab discontinuers 
compared with the standard care group: this led to a situation whereby patients discontinuing 
adalimumab had a more favourable long-term prognosis compared with those who had never received 
adalimumab (e.g. a patient who discontinued adalimumab at 36 weeks would still be deriving benefit 
from therapy 20 years later). The ERG did not consider this to be clinically plausible and noted that 
removing this assumption increased the ICER for adalimumab. The ERG had further concerns that the 
company’s additional analyses did not include the committee’s preferred assumptions regarding 
surgery. The ERG also noted that the company’s analyses which included the new definition of partial 
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response had been applied only to the transition probabilities, but should also have impacted on health 
state costs, discontinuation rates and utilities. The ERG undertook further exploratory analyses which 
included the company’s NMA, the corrected discontinuation rate and alternative assumptions regarding 
the mean lifetime number of  wide excisions. Based on the ERG’s exploratory analyses of this revised 
model, the committee concluded that the maximum possible ICER for adalimumab compared with 
supportive care was between £28,500 and £33,200 per QALY gained [27]. In May 2016, NICE 
published its FAD which makes the following recommendations:  
 
“1.1 Adalimumab is recommended, within its marketing authorisation, as an option for treating active 
moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional 
systemic therapy. The drug is recommended only if the company provides it at the price agreed in the 
PAS.  
 
1.2 Assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear 
evidence of response, defined as:   a reduction of 25% or more in the total AN count and   no increase in abscesses and draining fistulas.” 
 
5.1 Consideration of clinical and cost-effectiveness issues 
This section discusses the key issues considered by the appraisal committee. The full list can be found 
in the FAD [27]. 
 
5.1.1 Appropriate HiSCR threshold for determining treatment response and continuation 
The committee considered how clinicians assess disease severity and response to treatment in people 
with HS. The clinical experts considered that the HiSCR is a reliable and reproducible tool, which has 
been validated and is relevant to clinical practice, but noted that the minimum clinically important 
difference (MCID) has not been established. Clinical experts were aware that according to the HiSCR 
validation study, response was defined as a 50% reduction in total AN count, with no increase in 
abscesses or draining fistulas from baseline. However, clinical experts considered that the 50% 
threshold was too high, and stated that a 25% reduction in AN count, provided there was no increase in 
abscesses or draining fistulas from baseline, would reflect a treatment response. Clinical experts 
suggested that if the reduction in AN count was between 25% and 50%, they would continue with the 
existing treatment but may prescribe additional concomitant treatments (e.g. anti-inflammatories, 
retinoids and antibiotics) to improve response. The committee heard from experts that they would stop 
treatment if the reduction in AN count was lower than 25%, or if there was an increase in abscesses or 
draining fistulas. The clinical experts stated that it was important to also use PROMs when monitoring 
people with HS (in particular, the DLQI, the pain visual analogue scale [VAS] and the SF-36, even 
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though they are not specific to this indication), because physician-reported and patient-reported scores 
do not always correlate. The committee concluded that it is appropriate to use HiSCR for assessing 
response to treatment, with supporting information provided by PROMs.  
 
5.1.2 Clinical effectiveness of adalimumab for HS 
The committee discussed the clinical evidence for adalimumab and noted that people treated with 
adalimumab were more likely to have a clinical response than people treated with placebo and that this 
difference was significant. The committee was aware that the benefit with adalimumab was greater in 
PIONEER II than PIONEER I, possibly because PIONEER II patients appeared to have had less severe 
disease than those in PIONEER I, and had potentially received higher levels of systemic antibiotics. 
The company noted that only 19% of patients in PIONEER II took oral antibiotics during the trial. The 
committee noted that the company had not originally undertaken a formal meta-analysis and was 
concerned that they had given contradictory views on whether the PIONEER trials had similar or 
heterogeneous baseline characteristics, but concluded that the trials were generalisable to UK clinical 
practice. The committee was concerned that the OLE study only had data up to 72 weeks, given that 
adalimumab may be used for many years, and that full data were only available for 26% of enrolled 
patients. The committee concluded that adalimumab provided significant benefits compared with 
placebo, but these had not been shown over the long-term. The committee was also aware that 
adalimumab showed a beneficial effect on the SF-36 (collected in PIONEER I) and the DLQI (collected 
in PIONEER I and II) but noted that the difference between adalimumab and placebo was not significant 
for all components of the SF-36, and that the difference between arms in DLQI improvement at week 
12 was not greater than the MCID. The committee considered that the DLQI may have underestimated 
the beneficial effects of adalimumab, based on the clinical experts’ comments that people with chronic 
skin conditions can develop coping mechanisms, which may result in lower DLQI scores than would 
be expected. The committee concluded that adalimumab had a statistically significant and clinically 
meaningful positive effect on HRQoL. 
 
5.1.3 Uncertainty surrounding the cost-effectiveness of adalimumab for HS 
The committee attempted to identify the most plausible ICER for adalimumab compared with 
supportive care. The committee considered that the resource use assumptions in the ERG’s new 
exploratory analyses, provided after consultation, were more realistic than the assumptions in the 
company’s revised model. The committee also preferred the ERG’s assumption that there is no lifelong 
difference in prognosis between people who previously had adalimumab and then stopped treatment, 
and those who had never had the drug. It agreed with the ERG’s corrected discontinuation rate for 
weeks 12-36. Based on the ERG’s exploratory analyses, the committee concluded that the maximum 
possible probabilistic ICER for adalimumab compared with supportive care was between £28,500 and 
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£33,200 per QALY gained. However, the committee considered that the most plausible ICER would be 
lower than this for several reasons. First, the ERG’s assumption of a maximum of 4 wide excisions over 
a patient’s lifetime may be an underestimate, and the committee understood that the ICER reduced as 
the number of wide excisions increased. Second, the committee acknowledged that adalimumab may 
be associated with short-term improvements in psychological wellbeing after treatment is stopped, and 
so considered that the ERG’s assumption about prognosis was possibly pessimistic and may have 
overestimated the ICER. The committee also considered that if its preferred definitions of partial 
response and non-response had been incorporated in the ERG’s exploratory analyses, the ICER would 
have been reduced because continued treatment in people for whom a drug is not effective would be 
minimised.  
 
6. APPRAISAL COMMITTEE’S KEY CONCLUSION 
The committee concluded that adalimumab provided significant benefits compared with placebo, but 
that these had not been shown over the long-term. The committee also concluded that the maximum 
possible ICER for adalimumab compared with supportive care was between £28,500 and £33,200 per 
QALY gained. The committee was certain that the most plausible ICER would be lower than this for 
several reasons, including the possibility that the ERG had underestimated the number of wide excisions 
and was pessimistic in its assumption about prognosis. The committee also considered that if its 
preferred definitions of partial response and non-response had been incorporated in the ERG’s 
exploratory analysis, as well as the gains in HRQoL not already included in the QALY calculations, the 
ICER would have reduced further. 
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Table 1: HiSCR response categories 
HiSCR-based state 
definition 
HiSCR-based state description 
High response At least 75% total AN count reduction, with no increase in abscesses or 
draining fistulas from baseline 
Response At least 50% but less than 75% AN reduction, with no increase in abscesses 
or draining fistulas from baseline 
Partial response At least 25% but less than 50% AN reduction, with no increase in abscesses 
or draining fistulas from baseline; or at least 25% AN reductions, with an 
increase in abscesses and/or draining fistulas 
No response Defined as less than 25% AN reduction 
HiSCR - Hidradenitis Suppurativa Clinical Response; AN - abscess and inflammatory nodule  
 
Table 2: Evidence used to inform the model transition matrices 
Matrix description Source 
Standard care – induction phase 
Week 0-12 Cross-tabs of outcomes based on pooling of patients initially 
randomised to the placebo groups within PIONEER I/II 
Standard care – maintenance phase 
Week 12-36 Cross-tabs of outcomes for patients initially randomised to the 
placebo group in PIONEER II who subsequently continued on 
placebo during maintenance. 
Week 36+ GLM based on 12-36 week data described above 
Adalimumab – induction phase 
Week 0-12 Cross-tabs of outcomes based on pooling of patients initially 
randomised to adalimumab 40mg EW groups within PIONEER 
I/II. 
Maintenance phase – adalimumab 12-week responders 
Week 12-36 Cross-tabs of adalimumab 40mg EW patients re-randomised to 
adalimumab 40mg EW after responding at 12-weeks in 
PIONEER I/II. 
Week 36-48 GLM based on weeks 0-24 of M12-555 OLE study (including 
LOCF imputation as <50% patients had 24-weeks follow-up 
data). 
Week 48+ Same as above except the probability of transiting from 
adalimumab no response state to standard care no response state 
is cubed. 
Maintenance phase – adalimumab 12-week non-responders and subsequent discontinuers 
Week 12-36 Cross-tabs of patients randomised to adalimumab 40mg EW in 
PIONEER I/II who switched to placebo in the maintenance 
period (irrespective of whether they achieved an induction 
response on adalimumab). 
Week 36+ GLM based on week 12-36 data described above 
GLM – generalised linear model; OLE – open-label extension; LOCF – last observation carried forward; mg – milligram; 
EW – every week 
 
 
